Jiangsu Hengrui Pharmaceuticals Co.,Ltd (JHPCY)

Market Cap	44.92B -26.5%
Revenue (ttm)	4.90B +6.0%
Net Income	1.32B +18.9%
EPS	0.34 +15.4%
Shares Out	n/a
PE Ratio	36.13
Forward PE	30.14
Dividend	0.06 (0.48%)
Ex-Dividend Date	Apr 30, 2026

Volume	100
Open	12.25
Previous Close	n/a
Day's Range	12.25 - 12.25
52-Week Range	11.50 - 20.00
Beta	0.04
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 27, 2026

About JHPCY

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Employees: 20,602
• Stock Exchange: OTCMKTS
• Ticker Symbol: JHPCY

Financial Performance

In 2025, JHPCY's revenue was 31.63 billion, an increase of 13.02% compared to the previous year's 27.98 billion. Earnings were 7.71 billion, an increase of 21.69%.

Financial numbers in CNY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 28, 2026

Data Sources Report a data error